Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of resmetirom in patients with non-alcoholic steatohepatitis (NASH) and fibrosis
2018-004012-22Phase 3Active
- Sponsor
- Madrigal Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoint: NASH Resolution Response at Week 52. Started May 2019; status: active.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2018-004012-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004012-22.